Why Compugen Ltd.’s (CGEN) Stock Is Down 5.42%
As of Wednesday, September 23, Compugen Ltd.’s CGEN share price has dipped by 5.42%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Commentary & Analysis
Why Compugen Ltd.’s (CGEN) Stock Is Down 5.25%
As of Friday, August 28, Compugen Ltd.’s CGEN share price has dipped by 5.25%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Compugen Ltd.’s (CGEN) Stock Is Up 7.14%
As of Tuesday, August 25, Compugen Ltd.’s CGEN share price has surged by 7.14%, which has investors questioning if this is right time to sell.Michael Rose
Why Compugen Ltd.’s (CGEN) Stock Is Down 7.92%
As of Friday, August 21, Compugen Ltd.’s CGEN share price has dipped by 7.92%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Compugen Ltd.’s (CGEN) Stock Is Up 5.19%
As of Thursday, July 09, Compugen Ltd.’s CGEN share price has surged by 5.19%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | CGEN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $218.8 | $250.1 | 28% |
|
| Shares Out (Mil) | 94.6 | 54.0 | 61% |
|
| Institutional Ownership | 98.7% | 93.1% | 81% |
|
| Float (Mil) | 94.5 | 41.4 | 59% |
|
| Beta | 2.79 | 0.95 | 97% |
|
| Avg Daily Volume (000s) | 154 | 661 | 40% |
|
| Price Change (52-week) |
44.4% | 49.5% | 82% |
|
| Growth | CGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 105.2% | 12.5% | 99% |
|
| Net Income (5yr) | 26.1% | (10.1%) | 81% |
|
| EPS (5yr) | 24.7% | 15.8% | 75 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 94.3% | (15.7%) | 98% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.087) | ($0.330) | ($0.367) | |
| Month Ago EPS | ($0.087) | ($0.330) | ($0.367) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.085) | ($0.340) | ($0.365) | |
| Year/Year Chg | 17.6% | (187.3%) | (202.4%) | |
| Financials | CGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $74 | $37 | 24% |
|
| Net Income (TTM) (Mil) | $35 | ($44) | 52% |
|
| EPS (TTM) | $0.373 | ($1.600) | 51% |
|
| Operating Cash Flow (TTM) (Mil) | na | ($33) | na |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 21% |
|
| Enterprise Value (Q1) (Mil) | $111 | $175 | 22% |
|
| Valuation | CGEN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.46 | 2.36 | 60% |
|
| P/E | 6.2 | 18.9 | 7% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.3 | 1.0 | 11% |
|
| Ratios | CGEN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 86.9% | 67.3% | 92% |
|
| Net Margin | 47.6% | (74.8%) | 96% |
|
| ROA | 28.3% | (47.6%) | 98% |
|
| ROE | 47.9% | (54.9%) | 92% |
|
| Liabilities to Assets | 35.9% | 29.3% | 27% |
|
| F-Score | 4 | 3 | 33% |
|
Compugen Ltd. did not pass any screens on 10/2/2026.
